Groupe la Francaise Acquires Shares of 127,200 Simulations Plus, Inc. $SLP

Groupe la Francaise bought a new position in Simulations Plus, Inc. (NASDAQ:SLP) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 127,200 shares of the technology company’s stock, valued at approximately $2,329,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Simulations Plus in the second quarter worth about $25,000. Quarry LP purchased a new stake in Simulations Plus in the 3rd quarter valued at about $28,000. GAMMA Investing LLC grew its stake in Simulations Plus by 26.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock worth $52,000 after acquiring an additional 585 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Simulations Plus by 343.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after acquiring an additional 3,084 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC purchased a new position in shares of Simulations Plus during the second quarter worth approximately $77,000. 78.08% of the stock is currently owned by institutional investors.

Simulations Plus Stock Performance

Shares of SLP opened at $18.43 on Tuesday. The company has a 50 day moving average price of $18.33 and a 200-day moving average price of $15.67. Simulations Plus, Inc. has a fifty-two week low of $11.09 and a fifty-two week high of $21.01. The stock has a market capitalization of $372.84 million, a PE ratio of 46.07 and a beta of 1.33.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.07. The firm had revenue of $21.89 million for the quarter, compared to the consensus estimate of $20.90 million. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SLP shares. Weiss Ratings raised shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 10th. Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Craig Hallum cut Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price for the company. in a report on Thursday, June 18th. Finally, William Blair downgraded Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $17.25.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter Woltosz sold 4,177 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total transaction of $77,023.88. Following the sale, the director owned 3,202,131 shares of the company’s stock, valued at approximately $59,047,295.64. This trade represents a 0.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is currently owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.